Literature DB >> 34182493

Concomitant Use of High-dose Methotrexate and Glycyrrhizin Affects Pharmacokinetics of Methotrexate, Resulting in Hepatic Toxicity.

Kentaro Abe1,2, Tsukasa Higurashi1, Mio Takahashi1, Ayako Maeda-Minami1, Yohei Kawano1, Satoru Miyazaki1, Yasunari Mano3.   

Abstract

BACKGROUND/AIM: High-dose methotrexate is a therapy for acute leukemia, malignant lymphoma, and osteosarcoma. Glycyrrhizin has been used to treat hepatic dysfunction caused by high-dose methotrexate. However, few studies have investigated the interaction between glycyrrhizin and high-dose methotrexate.
MATERIALS AND METHODS: Male Wistar rats were treated with high-dose methotrexate (500 or 1,000 mg/kg) alone, or with co-administration of 100 mg/kg glycyrrhizin. Plasma concentrations of methotrexate, alanine aminotransferase, aspartate aminotransferase, and total bilirubin were measured.
RESULTS: At both methotrexate doses, the blood concentration of methotrexate was significantly increased and total clearance was significantly reduced using co-administration of glycyrrhizin compared with methotrexate alone, which led to increased levels of hepatic enzymes. These results suggest that glycyrrhizin significantly increases the plasma level and delays the clearance of methotrexate, resulting in hepatic toxicity.
CONCLUSION: The concomitant use of methotrexate and glycyrrhizin should be considered with caution.
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  High-dose methotrexate (HD-MTX); blood concentration; glycyrrhizin; hepatic dysfunction; pharmacokinetic interactions; rat

Year:  2021        PMID: 34182493     DOI: 10.21873/invivo.12487

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  1 in total

1.  Identification of Ferroptosis-Related Genes as Biomarkers for Sarcoma.

Authors:  Zhiyuan Guan; Shengfu Liu; Liying Luo; Zhong Wu; Shan Lu; Zhiqiang Guan; Kun Tao
Journal:  Front Cell Dev Biol       Date:  2022-03-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.